Prof. Dr. med. Sibylle Loibl

Prof. Dr. med. Sibylle Loibl is a leading German gynecologist and a globally recognized authority in breast cancer research. With more than 30 years of experience, she has devoted her career to developing more effective therapies that not only improve survival rates but also enhance the quality of life for breast cancer patients. Since 2015, she has chaired the German Breast Group (GBG), one of the world’s foremost networks for clinical breast cancer trials. In 2017, she also took on the role of Managing Director of GBG Forschungs GmbH, focusing on the design and execution of clinical studies.

In her clinical practice, she treats patients at the oncological group practice at Bethanien Hospital in Frankfurt and sits on the tumor board at Sana Klinikum Offenbach. Under her leadership, the GBG has launched more than 115 studies and enrolled over 67,000 patients in clinical trials across the globe.

She completed her doctorate at the Ruprecht-Karls-University of Heidelberg and trained in gynecology and obstetrics at the university hospitals in Heidelberg and Frankfurt am Main. In 2007, she qualified as a university lecturer in gynecology and obstetrics at Goethe University Frankfurt, where she was appointed Associate Professor in 2012. Since then, she has played a pivotal role in clinical oncology. Her research spans every phase of breast cancer treatment, with a particular focus on neoadjuvant and post-neoadjuvant therapies, translational research, and the management of breast cancer during pregnancy and among specific patient groups. She is a key figure in numerous national and international professional societies and is highly regarded for her expertise in the development and conduct of clinical trials.